Counterpain-PXM Special Precautions

If local irritation develops, the use of the gel should be discontinued and appropriate therapy instituted as necessary. Avoid occlusive dressing. Do not apply to the eyes, mucosa or to open skin lesions or skin conditions affecting the site of application.
Use in pregnancy & lactation: The safety of Counterpain-PXM use during pregnancy or lactation has not yet been established. Counterpain-PXM inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclooxygenase enzyme. This effect, as with other nonsteroidal anti-inflammatory agents, has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when piroxicam administration was continued into late pregnancy. Nonsteroidal anti-inflammatory drugs are also known to induce closure of the ductus arteriosus in infants. A preliminary study indicates that following oral administration, piroxicam exists in maternal milk in a concentration of approximately 1% of that reached in plasma after oral administration. Counterpain-PXM is not recommended for use in nursing mothers as the clinical safety has not been established.